VALNEVA SE
Campus Bio-Ouest | 6, Rue Alain Bombard
44800 Saint-Herblain, France



Valneva Announces Removal of FDA-Recommended Pause on
Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates
to the Prescribing Information
Saint Herblain (France), August 7, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a
specialty vaccine company, today announced that the FDA has removed its recommended pause in
the use of IXCHIQ® in individuals 60 years of age and older and has approved updates to the
Prescribing Information (PI) for IXCHIQ®. IXCHIQ® remains indicated in the United States for the
prevention of disease caused by the Chikungunya Virus (CHIKV) in individuals 18 years of age and
older who are at high risk of exposure to CHIKV.
The FDA decision follows the announcement in July by the European Medicines Agency (EMA)1
which recommended the lifting of temporary restrictions in elderly people after the conclusion of a
thorough review of IXCHIQ® by its safety committee (PRAC).
The PI has been updated to reflect reports of Serious Adverse Events, primarily among elderly
individuals with multiple underlying health conditions, following a mass vaccination campaign in La
Réunion in response to a severe chikungunya outbreak.
The FDA noted that for most U.S. travelers the risk of exposure to CHIKV is low and therefore, the
product is not advisable for most of them. IXCHIQ® should be given when there is a significant risk
of chikungunya infection and only after careful consideration of the benefits and risks. Healthcare
professionals are reminded that IXCHIQ® is contraindicated in individuals with weakened immune
systems due to disease or immunosuppressive treatments, as stated in IXCHIQ®’s product label in
the U.S., Europe and other territories.
Furthermore, the product’s Warnings and Precaution section has been expanded to reflect the SAE
profile observed, especially in people above 65 years of age and older with one or more chronic
medical conditions.
Ongoing FDA reviews are progressing regarding potential extension of IXCHIQ®’s label to
adolescents and inclusion of additional persistence data.
About Chikungunya
Chikungunya virus (CHIKV) is a mosquito-borne viral disease spread by the bites of infected Aedes
mosquitoes which causes fever, severe joint and muscle pain, headache, nausea, fatigue and rash.
Joint pain is often debilitating and can persist for weeks to years2.
In 2004, the disease began to spread quickly, causing large-scale outbreaks around the world. Since
the re-emergence of the virus, CHIKV has now been identified in over 110 countries in Asia, Africa,
Europe and the Americas3. Between 2013 and 2023, more than 3.7 million cases were reported in
the Americas4 and the economic impact is considered to be significant. The medical and economic

1
Ixchiq: temporary restriction on vaccinating people 65 years and older to be lifted | European Medicines Agency (EMA)
2
https://jvi.asm.org/content/jvi/88/20/11644.full.pdf
3
https://cmr.asm.org/content/31/1/e00104-16
4
PAHO/WHO data: Number of reported cases of chikungunya fever in the Americas (Cumulative Cases 2018-2023 and Cases per year
2013-2017). https://www.paho.org/data/index.php/en/mnu-topics/chikv-en/550-chikv-weekly-en.html. Last accessed 01 Aug 2023.
burden is expected to grow with climate change as the mosquito vectors that transmit the disease
continue to spread geographically. As such, the World Health Organization (WHO) has highlighted
chikungunya as a major public health problem.5
About Valneva SE
We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic
vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and
targeted approach, applying our deep expertise across multiple vaccine modalities, focused on
providing either first-, best- or only-in-class vaccine solutions.
We have a strong track record, having advanced multiple vaccines from early R&D to approvals,
and currently market three proprietary travel vaccines.
Revenues from our growing commercial business help fuel the continued advancement of our
vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical
development, which is partnered with Pfizer, the world’s most clinically advanced tetravalent Shigella
vaccine candidate, as well as vaccine candidates against the Zika virus and other global public
health threats. More information is available at www.valneva.com.

Media and Investor Relations Contacts
Laetitia Bachelot-Fontaine Joshua Drumm, Ph.D.
VP Global Communications & European Investor Relations VP Global Investor Relations
M +33 (0)6 4516 7099 M +001 917 815 4520
laetitia.bachelot-fontaine@valneva.com joshua.drumm@valneva.com

Forward-Looking Statements
This press release contains certain forward-looking statements relating to the business of Valneva,
including with respect to use and regulatory review of existing products. In addition, even if the actual
results or development of Valneva are consistent with the forward-looking statements contained in
this press release, those results or developments of Valneva may not be sustained in the future. In
some cases, you can identify forward-looking statements by words such as “could,” “should,” “may,”
“expects,” “anticipates,” “believes,” “intends,” “estimates,” “aims,” “targets,” or similar words. These
forward-looking statements are based largely on the current expectations of Valneva as of the date
of this press release and are subject to a number of known and unknown risks and uncertainties and
other factors that may cause actual results, performance or achievements to be materially different
from any future results, performance or achievement expressed or implied by these forward-looking
statements. In particular, the expectations of Valneva could be affected by, among other things,
uncertainties and delays involved in the development and manufacture of vaccines, unexpected
clinical trial results or new adverse events, unexpected regulatory actions or delays, competition in
general, currency fluctuations, the impact of the global and European credit crisis, and the ability to
obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical
studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these
risks and uncertainties, there can be no assurance that the forward-looking statements made in this
press release will in fact be realized. Valneva is providing this information as of the date of this press


5
Geographical expansion of cases of dengue and chikungunya beyond the historical areas of transmission in the Region of the
Americas (who.int)
release and disclaims any intention or obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events, or otherwise.